{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:17:48Z","timestamp":1787627868647,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jns.2024.123202","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T01:53:54Z","timestamp":1724810034000},"page":"123202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Effect of concomitant use of esomeprazole on levodopa pharmacokinetics and clinical symptoms in patients with Parkinson's disease"],"prefix":"10.1016","volume":"465","author":[{"given":"Noriyuki","family":"Miyaue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Yabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2024.123202_bb0005","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1056\/NEJM2003ra020003","article-title":"Alzheimer\u2019s disease and Parkinson\u2019s disease","volume":"348","author":"Nussbaum","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2024.123202_bb0010","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/mds.25945","article-title":"The prevalence of Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"29","author":"Pringsheim","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2024.123202_bb0015","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.3233\/JPD-181474","article-title":"The emerging evidence of the Parkinson pandemic","volume":"8","author":"Dorsey","year":"2018","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.jns.2024.123202_bb0020","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1212\/WNL.0000000000012868","article-title":"Guideline subcommittee of the AAN, dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary: a report of the AAN guideline subcommittee","volume":"97","author":"Pringsheim","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2024.123202_bb0025","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/00003088-200241040-00003","article-title":"Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson\u2019s disease","volume":"41","author":"Deleu","year":"2002","journal-title":"Clin. Pharmacokinet."},{"issue":"Supplement 3","key":"10.1016\/j.jns.2024.123202_bb0030","doi-asserted-by":"crossref","first-page":"S580","DOI":"10.1002\/mds.22037","article-title":"Pharmacokinetics and pharmacodynamics of levodopa","volume":"23","author":"Nutt","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2024.123202_bb0035","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/mdc3.12908","article-title":"Impact of residual drug in the pharynx on the delayed-on phenomenon in Parkinson\u2019s disease patients","volume":"7","author":"Fukae","year":"2020","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.jns.2024.123202_bb0040","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jns.2012.05.010","article-title":"Plasma levodopa peak delay and impaired gastric emptying in Parkinson\u2019s disease","volume":"319","author":"Doi","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2024.123202_bb0045","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3389\/fnagi.2017.00206","article-title":"Protein-restricted diets for ameliorating motor fluctuations in Parkinson\u2019s disease","volume":"9","author":"Wang","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.jns.2024.123202_bb0050","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.parkreldis.2021.04.009","article-title":"Gastrointestinal surgery improved the absorption of levodopa in Parkinson\u2019s disease","volume":"87","author":"Miyaue","year":"2021","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2024.123202_bb0055","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00415-021-10473-1","article-title":"Helicobacter pylori infection is associated with a poor response to levodopa in patients with Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"269","author":"Zhong","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2024.123202_bb0060","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41467-019-08294-y","article-title":"Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson\u2019s disease","volume":"10","author":"van Kessel","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jns.2024.123202_bb0065","first-page":"264","article-title":"Gastric acid secretion and absorption of levodopa in patients with Parkinson\u2019s disease\u2014the effect of supplement therapy to gastric acid","volume":"34","author":"Yazawa","year":"1994","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1016\/j.jns.2024.123202_bb0070","doi-asserted-by":"crossref","first-page":"251","DOI":"10.56808\/3027-7922.2461","article-title":"Increasing the solubility of levodopa and carbidopa using ionization approach","volume":"44","author":"Krisai","year":"2020","journal-title":"Thai J. Pharm. Sci. (TJPS)."},{"key":"10.1016\/j.jns.2024.123202_bb0075","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/gut.41.4.452","article-title":"Helicobacter pylori independent chronological change in gastric acid secretion in the Japanese","volume":"41","author":"Kinoshita","year":"1997","journal-title":"Gut"},{"key":"10.1016\/j.jns.2024.123202_bb0080","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2024.123202_bb0085","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/mdc3.12921","article-title":"Levodopa equivalent dose conversion factors: an updated proposal including Opicapone and safinamide","volume":"7","author":"Schade","year":"2020","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.jns.2024.123202_bb0090","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society UPDRS revision task force, Movement Disorder Society-sponsored revision of the unified Parkinson\u2019s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2024.123202_bb0095","article-title":"Concomitant use of magnesium oxide significantly decreases absorption of levodopa preparations in patients with Parkinson\u2019s disease","volume":"9","author":"Miyaue","year":"2023","journal-title":"Clin. Park. Relat. Disord."},{"key":"10.1016\/j.jns.2024.123202_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056060","article-title":"Proton pump inhibitor use in the U.S. ambulatory setting, 2002\u20132009","volume":"8","author":"Rotman","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jns.2024.123202_bb0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/pds.4135","article-title":"Long-term use of proton pump inhibitors and prevalence of disease- and drug-related reasons for gastroprotection-a cross-sectional population-based study","volume":"26","author":"Wallerstedt","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.jns.2024.123202_bb0110","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/mds.23566","article-title":"Prevalence of small intestinal bacterial overgrowth in Parkinson\u2019s disease","volume":"26","author":"Gabrielli","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2024.123202_bb0115","article-title":"High prevalence of gastroesophageal reflux disease in Parkinson\u2019s disease: a questionnaire-based study","volume":"2013","author":"Maeda","year":"2013","journal-title":"Parkinsons Dis."},{"key":"10.1016\/j.jns.2024.123202_bb0120","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00198-015-3365-x","article-title":"Proton-pump inhibitors and risk of fractures: an update meta-analysis","volume":"27","author":"Zhou","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.jns.2024.123202_bb0125","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1136\/jnnp-2013-307307","article-title":"Bone health in Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"85","author":"Torsney","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2024.123202_bb0130","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1001\/jama.2013.280490","article-title":"Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency","volume":"310","author":"Lam","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jns.2024.123202_bb0135","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/mds.27301","article-title":"Parkinson study group-DATATOP investigators, vitamin B12 and homocysteine levels predict different outcomes in early Parkinson\u2019s disease","volume":"33","author":"Christine","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2024.123202_bb0140","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1212\/WNL.0b013e31823a0ee4","article-title":"Neuropathy in Parkinson disease: prevalence and determinants","volume":"77","author":"Rajabally","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2024.123202_bb0145","article-title":"Proton pump inhibitor use and the risk for Parkinson\u2019s disease: a nationwide population-based study in Taiwan","volume":"102","author":"Chen","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jns.2024.123202_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0295981","article-title":"Potential risk of proton pump inhibitors for Parkinson\u2019s disease: a nationwide nested case-control study","volume":"18","author":"Hong","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.jns.2024.123202_bb0155","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00228-004-0841-1","article-title":"A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects","volume":"60","author":"Hassan-Alin","year":"2005","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jns.2024.123202_bb0160","doi-asserted-by":"crossref","first-page":"e2443","DOI":"10.1212\/WNL.0000000000201204","article-title":"Association between microbial tyrosine decarboxylase gene and levodopa responsiveness in patients with Parkinson disease","volume":"99","author":"Zhang","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2024.123202_bb0165","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","article-title":"Proton pump inhibitors affect the gut microbiome","volume":"65","author":"Imhann","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jns.2024.123202_bb0170","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/s41467-017-00796-x","article-title":"Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus","volume":"8","author":"Llorente","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jns.2024.123202_bb0175","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1023\/A:1018970323716","article-title":"Upper gastrointestinal pH in seventy-nine healthy, elderly, North American men and women","volume":"10","author":"Russell","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jns.2024.123202_bb0180","doi-asserted-by":"crossref","DOI":"10.1177\/1756283X17745776","article-title":"Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date","volume":"11","author":"Sugano","year":"2018","journal-title":"Ther. Adv. Gastroenterol."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X2400337X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X2400337X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T02:32:46Z","timestamp":1726021966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X2400337X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":36,"alternative-id":["S0022510X2400337X"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2024.123202","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of concomitant use of esomeprazole on levodopa pharmacokinetics and clinical symptoms in patients with Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2024.123202","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"123202"}}